title: Effects of carvedilol during exercise.
abstract: The effect of carvedilol on cardiovascular and physical performance parameters at rest and during exercise was evaluated in an open, uncontrolled study. Assessments were made at rest, at one-half anaerobic threshold (1/2AT), at AT, and at maximal work load (WLmax) before and after 3 weeks of treatment with 12.5 mg carvedilol once daily for 1 week, followed by 25 mg carvedilol once daily for 2 weeks. Ten well-conditioned healthy male volunteers maintained their regular training program during the study, and all completed the study. End-of-study measures of physical performance (time to WLmax, WLmax, and VO2/kg) and behavioral measures (Borg scale) of perceived exertion were unchanged from prestudy values. End-of-study diastolic BP (DBP) at rest and at WLmax was unchanged compared with prestudy values (mean +/- SD; 81.0 +/- 7.38 and 84.4 +/- 4.95 mm Hg, respectively, compared with 82.0 +/- 8.88 and 85.0 +/- 7.07 mm Hg, respectively). Mean +/- SD change from prestudy to end-of-study baseline resting systolic BP (SBP) was a reduction of 11.5 +/- 8.83 mm Hg, and mean +/- SD change from prestudy to end-of-study SBP at WLmax was a reduction of 20.0 +/- 12.25 mm Hg. Mean +/- SD change from prestudy to end-of-study resting heart rate (HR) a reduction of 7.8 +/- 18.45 beats/min, and mean +/- SD change from prestudy to end-of-study HR at WLmax was a reduction of 19.7 +/- 9.24 beats/min. The effect of carvedilol thus represents a combination of reduction in resting systolic BP and HR and attenuation of the exercise-induced changes in these parameters.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cardiovascular Department, Sophiahemmet, Stockholm, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Loefsjoegaard-Nilsson
authors.forename: B
authors.initials: B
authors.lastname: Atmer
authors.forename: M
authors.initials: M
authors.lastname: Gunolf
authors.forename: S
authors.initials: S
authors.lastname: Krug-Gourley
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D002227:Carbazoles / Q000494:pharmacology* / Q000627:therapeutic use; D000077261:Carvedilol; D004562:Electrocardiography; D015444:Exercise; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion / Q000502:physiology*; D011412:Propanolamines / Q000494:pharmacology* / Q000627:therapeutic use; D011659:Pulmonary Gas Exchange; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002227:Carbazoles; D011412:Propanolamines; D014665:Vasodilator Agents; D000077261:Carvedilol